Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 441 to 450 of 1090 total matches.
Eszopiclone (Lunesta), a New Hypnotic
The Medical Letter on Drugs and Therapeutics • Feb 28, 2005 (Issue 1203)
) on the first night.
DRUG INTERACTIONS — Like zolpidem, zaleplon
and the benzodiazepines, eszopiclone alone ...
Eszopiclone (Lunesta - Sepracor), a benzodiazepine-like drug, has been approved by the FDA for oral treatment of insomnia. It is the S-isomer of zopiclone (Imovane, and others in Canada), which has been available in other countries for almost 20 years. Unlike similar drugs such as zolpidem (Ambien) or zaleplon (Sonata), Lunesta is not being restricted in its labeling to short-term use. Like other hypnotics, eszopiclone is a schedule IV drug.
Rofecoxib for Osteoarthritis and Pain
The Medical Letter on Drugs and Therapeutics • Jul 02, 1999 (Issue 1056)
with moderate hepatic insufficiency.
DRUG INTERACTIONS — Cytochrome P450 enzymes play a minor role ...
Rofecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis, acute pain and menstrual pain.
Lacosamide for Epilepsy
The Medical Letter on Drugs and Therapeutics • Jun 29, 2009 (Issue 1315)
.
DRUG INTERACTIONS — Although lacosamide is a
substrate and inhibitor of CYP2C19, it does not appear ...
The FDA has approved lacosamide (Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.
Citalopram, Escitalopram and the QT Interval
The Medical Letter on Drugs and Therapeutics • Jul 22, 2013 (Issue 1421)
drug
interactions. Bupropion (Wellbutrin, and generics) is an
alternative to an SSRI for patients who ...
In 2011, the FDA asked the manufacturers of the selective
serotonin reuptake inhibitor (SSRI) citalopram
(Celexa, and generics) to lower the maximum daily
dosage of the drug because of a dose-related increase
in the QT interval. Since then, some of our readers
have asked whether escitalopram (Lexapro, and generics),
the active enantiomer of citalopram, could have the
same effect.
In Brief: Telithromycin Hepatotoxicity
The Medical Letter on Drugs and Therapeutics • Apr 24, 2006 (Issue 1233)
, exacerbation of myasthenia gravis, hepatotoxicity and drug interactions. A recent
report (Ann Intern Med 2006 ...
Telithromycin (Ketek) is an oral erythromycin derivative FDA-approved for treatment of mild to moderate community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial sinusitis (Med Lett Drugs Ther 2004; 46:66). It is generally considered an alternative antibiotic because of its cost, potential for adverse effects including visual disturbances, exacerbation of myasthenia gravis, hepatotoxicity and drug interactions. A recent report (Ann Intern Med 2006; 144:415) described serious hepatotoxicity probably related to telithromycin in three patients, including one who died...
Correction: The EarCheck Middle Ear Monitor
The Medical Letter on Drugs and Therapeutics • Aug 11, 2008 (Issue 1292)
of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D., University of Washington ...
The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic membrane, but rather by its mobility.
Correction: CT Colonography
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008 (Issue 1301)
. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW: Manouchkathe Cassagnol, Pharm.D ...
(Med Lett Drugs Ther 2008; 50:94) In table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively.
Bleeding with Dabigatran (Pradaxa)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011 (Issue 1379)
of Dabigatran
Drug Interactions – Dabigatran is a substrate of the
P-glycoprotein (P-gp) transporter ...
The labeling of dabigatran etexilate (Pradaxa –
Boehringer Ingelheim), an oral direct thrombin inhibitor,
has recently been updated to include new dosing and
monitoring recommendations and a warning on the risk
of bleeding. Dabigatran etexilate was approved in the
US in 2010 for the prevention of thromboembolic stroke
in patients with non-valvular atrial fibrillation. It has been
shown to be more effective than warfarin (Coumadin,
and others) for this indication.
Olutasidenib (Rezlidhia) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
with olutasidenib
and for at least 2 weeks after the last dose.
DRUG INTERACTIONS — Olutasidenib is a CYP3A ...
Olutasidenib (Rezlidhia – Rigel), an oral isocitrate
dehydrogenase-1 (IDH1) inhibitor, has been
approved by the FDA for treatment of relapsed or
refractory acute myeloid leukemia (AML) in adults
with a susceptible IDH1 mutation. It is the second
drug that targets cancer metabolism to be approved
for this indication; ivosidenib (Tibsovo) was
approved in 2022.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e58-9 doi:10.58347/tml.2023.1673e | Show Introduction Hide Introduction
Capmatinib (Tabrecta) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
photosensitivity; patients should limit
direct ultraviolet exposure during treatment.
DRUG INTERACTIONS ...
The FDA has granted regular approval to the oral
kinase inhibitor capmatinib (Tabrecta – Novartis) for
treatment of metastatic non-small cell lung cancer
(NSCLC) in adults whose tumors have a mutation that
leads to mesenchymal-epithelial transition (MET)
exon 14 skipping. MET exon 14 skipping mutations
occur in 3-4% of NSCLC cases. The drug received
accelerated approval for the same indication in 2020
based on initial overall response rates and duration
of response.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-6 doi:10.58347/tml.2023.1674d | Show Introduction Hide Introduction